{"name":"MoonLake Immunotherapeutics AG","slug":"moonlake-immunotherapeutics-ag","ticker":"","exchange":"","domain":"moonlakeimmunotherapeutics.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Sonelokimab","genericName":"Sonelokimab","slug":"sonelokimab","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"Sonelokimab","genericName":"Sonelokimab","slug":"sonelokimab","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxOY1ZyVnVfbWFmVmRTZzYzSW41WUtHc2dzMXpkM0FWckMxQThKNjhHX0IyM3FBQjhkVFlHTmF0MkktU3N2cF9EcFdmVjI2Rk1wVmRjbDQwLTliY0VwRWI5anNhcGNDTHU0aXNBYWhYbHZEVHdLTE4yZmRlTGN0SDRKMURYMWlDR2QzUmVfeG1kdDQzVFFtOFlSUmJPckZmLVBqTEVMRDB5cXVjeGh2M0t3bXlHTjZBVXNWaE82N3ZuRG1mbGE3SHVid2Zaenh0UlJ5WkVlR0xJMzRORUhrQjlJQnNJdVllYkg0MmV3eXgxYW03clE5QVFScFRoNnh3V1JmU0tkZW1BTXJyb0UxTkNOWTNMX1RuSE5wYUpQTkIyWDQtaFk5TzFkbExQNmhYVkt1?oc=5","date":"2026-02-02","type":"regulatory","source":"GlobeNewswire","summary":"MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day - GlobeNewswire","headline":"MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upco","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxOUFFnVHJ3U1p3Y2NHeFExdGc3dm1McDdCcjNRMllvZFp5SmdnaWhRd3lPQ1c5bHkydkItemIwbGRpTTI3OEx1WE5fNTVweUIzVGJ2T0lMakV6ZGdhVmNsdEpGbkJMT3ZmdG4xd0xVaDlQUnRmY1JwWE1SbDhSZVhEdnFnUnNKdk9QeXMySTctNGV3TFBqckFndjBVZEh0VW1vZFNPWDJybzlFUUNPb1dZZkdsWThpWjI2eW84Yk5tcklQY1Vqd09Qd1RldTF0T0FuYk52UU5PeU41cHZtQjJ0ZGpsNW14SjFvTFNiV1lvTVpCR0hQMnYtbE9ONk5tTW01WHBlUTNRUF94dkxtVllDam5ZWU0?oc=5","date":"2026-01-08","type":"pipeline","source":"GlobeNewswire","summary":"MoonLake Immunotherapeutics Announces Positive Outcome from - GlobeNewswire","headline":"MoonLake Immunotherapeutics Announces Positive Outcome from","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOZVlxZ0JQOWNjeG9sS1Q0dWRHUjZtTFlPZVRFVHBPY3ZualJZUDB3cThHcmsxdHJXZFZPSjRvSHVzWFFJMjJOaENOWE4tVmVnS0szcEE0anZnZ1B0TTRUcnl0Q2hEdkwyNjNfZHhmY1hfX2Z6ZkZPZUZWWk1Ec0k1Tkt5LW1VbXZWdVZBanU3b1hWaXY2aEE0WFNkdlRkQQ?oc=5","date":"2025-11-05","type":"pipeline","source":"Yahoo Finance UK","summary":"MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering - Yahoo Finance UK","headline":"MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE95eW04V0l5Q0F2YWJLMTNjNWtyVzdXZmxyaUl1anVEVVNMdnlITlgzQ3Q5SFZ1clFXRGxrMlpjZ0dObUtYc1ZQSEowWkk2OU5XOWl3YnZsQ3J4T3NhU0pz?oc=5","date":"2025-10-06","type":"trial","source":"Nature","summary":"Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial - Nature","headline":"Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxNbF9LOGxua3Q4TG1SdkttRzRXX2ZCMndaSzMzajBJSDhyNThpamwwNEZuWjNjR3lwN3ZDazRIUWh5QmhTSXZQOWVycXhqMXYzazdqbHZyUnlzMWd1UHRDQmdOQ2FjYjFzR3lXaHktVkQzZ3lrRE5Vc1BCSXd1NGY1aFp6Z0pKRVA3bk1Qek01NXpYS08tUEhnaUtnQW5rLXgzVU9HWmlTV2dwWU5UbFJYelJBLTVGZWwwMDJpR1RHb0FSYlh0VzVHM25Fdi1vM2VXZTRGNm5zc0dvenpGVkFJcjg0S0x6dXNMRjgwNFlHOWlqZ2k0TkJCajlfR0tHR1VDcE5fT3JSZDBxQ2pOOTFRR2tNY2FNTng4RVBrRS05bklvSkVPaXh3UElkNG9vTW41aFFF?oc=5","date":"2025-09-28","type":"pipeline","source":"GlobeNewswire","summary":"MoonLake Immunotherapeutics reports on week 16 results of - GlobeNewswire","headline":"MoonLake Immunotherapeutics reports on week 16 results of","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOa012OGZwaUg0am54aDJhajlScC1Kb0EwY3J6VW1mWFpkeEZzQWJ0SjYydlRPNzQ5enE4SFhjcEJMQXUza3VZaDNVRERneE9ob2NicTRSdUtfbk4xZVdzSTlMeHU3Vi01eW1NVUxiVmZHV1l2OFdnb2VHNnhZSktEaFFqREttZENOeVY5Y19IMnFWNmtxQk94YU1zTWI?oc=5","date":"2025-08-05","type":"earnings","source":"Yahoo Finance","summary":"MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update - Yahoo Finance","headline":"MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNdFlzZDJGbnRBWEh6bFhpbEc3M3lBenZUbWE3QVY2MFBWVEdYektZOFlMQzZfTHNvOXlrQlA4aUdBRHEzQ29Ea0ZTeE00RkFZQ3QtSG9vSUlCWkpZQ3d2Y21UdlowYzNTODRsTDdBdXNicS04MXNzVEhHRlU3eFFaUFJ6cVlaX01IZzd0WjN1bXVfOUNPLVJJUmpB?oc=5","date":"2024-04-23","type":"pipeline","source":"European Biotechnology Magazine","summary":"Swiss Biotech Report reporting record turnover - European Biotechnology Magazine","headline":"Swiss Biotech Report reporting record turnover","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE9Jb3Z6aGdvQmpHYnhpdy1yN1N1elN1MjBsQWt0ZXVWeWJFUGVla2RuVWJrNW91MU9HTGhJZThKQlZqbmF2cW9MTnQ0WUY3X3NMVldWT3drQ2FtMExZcnl3M08xQkRSak51MGx1WnpnVW1SNDFodXk0Uzc4OEd5dw?oc=5","date":"2023-09-01","type":"pipeline","source":"Investopedia","summary":"Top Growth Stocks for September 2023 - Investopedia","headline":"Top Growth Stocks for September 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxQaElTdVdoaEN2YzdGdXVXYzZxVWR3NXpmMXNOOE40TlQ0bVBhNTR4MlBVcDFhMlVoRm1icHpMRk1pYmQxbUpjYm84Uk1LYUhXeHlYMnl6UEhqWnlXRDVRNm85bUE4ZVV3VVYyaG4xWkRBOFlSOVU5Wlc3R3hBTXpEY1hZeXNlSWh4aDN5dzBfNWE5T2xvZGREcWZYREo2ZElLeVdQT2pNVTI?oc=5","date":"2022-07-26","type":"pipeline","source":"Yahoo Finance","summary":"MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH - Yahoo Finance","headline":"MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE54Q05maXNQRGtVaU9vVkNLMEktUlNBWjZsYXljZzVhSTBWZmFuTU9GQ1ZjeEs1TGlLR3FNX1dUeXczR3BzU0QtYkk1ekFSQjFYcjN6R2k0bVJuSUU4S1lTMjVxR0xtV3FOcHc?oc=5","date":"2022-04-20","type":"pipeline","source":"Wiley Online Library","summary":"Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody sonelokimab: is there a role for IL-17F in disease reoccurrence? - Wiley Online","headline":"Maintenance of response in moderate-to-severe psoriasis after withdrawal of the interleukin (IL)-17A and IL-17F nanobody","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFA1a05MOGZ4cEl5a2JKNVVWSmVtOXJKVXBBUVROV2lOTFVhSFRXbU5VcnhUb0VJSjA2MlFaZHhPZlpGTlVSZW5XR0hCX0xFQ0lSc2pqX0cwMk5mUQ?oc=5","date":"2022-04-08","type":"pipeline","source":"marketbeat.com","summary":"MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis - marketbeat.com","headline":"MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2021-10-04","type":"pipeline","source":"Business Wire","summary":"MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing Tri-specific Nanobody® Sonelokimab - Busine","headline":"MoonLake Immunotherapeutics AG and Helix Acquisition Corp. Announce Business Combination Agreement to Create Publicly Li","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}